Loading
KORU Medical Systems, Inc. Stock: price and insider trades · United States
1 insider bought €87k of shares over the last 90 days, the latest by KALBERMATTEN ADAM R, filed 09 Sept 2026.
KORU Medical Systems, Inc.: what insiders have been doing
KORU Medical Systems, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 22 October 2025 to 22 October 2026, the disclosure feed for KORU Medical Systems, Inc. logged 37 filings by 12 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €87k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. Kalbermatten Adam R filed the largest purchase, €87k, on 9 September 2026, which represents 0.070% of the company's market value.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 37 filings, this issuer sits above that mark. Looking back to 2016, when coverage begins, insiders filed 172 purchases and 6 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 41.1 m USD and net income at -2.6 m USD.
The latest purchase dates back some time: it was published 45 days ago, on 9 September 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
557
Thresholds
n/a
Buy Volume
€8M
172 ops. · all time
Sell Volume
€10M
6 ops. · all time
Who traded when
BuySaleAdam R. Kalbermatten1 buy
Since the insiders bought
- -0.3%Entry US$3.15 · Close 21 Oct 2026 US$3.14
- +84.2%Entry US$2.28 · Close at T+365 US$4.20
- -9.7%Entry US$2.59 · Close at T+365 US$2.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,547 of 26,286 companies
34.9
score / 100
Value31
Quality39
FCF yld-0.3%
Earn yld-1.8%
EV/EBITDA·
ROE-11%
Gross mgn62%
Net mgn-6.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.11
Analyst consensus
4 analysts1.40/5
US$5.00Target US$6.25(+101%)US$8.00
Income statement
RevenueUS$41.1M
Gross profitUS$25.6M62% margin
EBITDA-US$2.2M-5% margin
Net income-US$2.6M-4.0% margin
Valuation
PER (forward)88.9x
P/Book8.0x
Beta0.39
Balance sheet & cash
Market capUS$143.6M
Total debtUS$3.5M
Free Cash Flow-US$494.1k
Debt / Equity18%
Profitability & ownership
ROE-10.5%
ROA-3.9%
% insiders8.2%
% institutions56.5%
Last declaration on 1 October 2026
Declarations557 total
5,119 shares0Common StockSEC:0001161697-26-000227:0
5,119 shares@ US$2.930.0098% mcap4.8% of flowCommon StockSEC:0001161697-26-000221:0
5,119 shares@ US$2.930.0098% mcap5.7% of flowCommon StockSEC:0001161697-26-000224:0
7,679 shares@ US$2.930.015% mcap5.7% of flowCommon StockSEC:0001161697-26-000222:0
5,119 shares@ US$2.930.0098% mcap3.9% of flowCommon StockSEC:0001161697-26-000223:0
5,119 shares@ US$2.930.0098% mcap8.9% of flowCommon StockSEC:0001161697-26-000225:0
32,000 shares@ US$3.160.070% mcap31.4% of flowCommon StockSEC:0001161697-26-000210:0
Canonical exit: 7 Dec 2026 (T+90)
75,000 shares0Common StockSEC:0001161697-26-000191:0
25,483 shares@ US$4.260.071% mcap34.5% of flowCommon StockSEC:0001161697-26-000191:1
25,483 shares@ US$4.26280.070% mcap34.1% of flowCommon StockSEC144:0001972481-26-000245
3,571 sharesCommon StockSEC:0001161697-26-000143:0
3,472 shares0Common StockSEC:0001161697-26-000088:0
3,472 shares0Common StockSEC:0001161697-26-000079:0
5,208 shares@ US$4.325.9% of flowCommon StockSEC:0001161697-26-000081:0
3,472 shares@ US$4.324.0% of flowCommon StockSEC:0001161697-26-000082:0
3,472 shares@ US$4.325.0% of flowCommon StockSEC:0001161697-26-000080:0
3,472 shares@ US$4.325.9% of flowCommon StockSEC:0001161697-26-000083:0
3,472 shares@ US$4.329.6% of flowCommon StockSEC:0001161697-26-000084:0
2,123 shares@ US$4.2860.1% of flowCommon StockSEC:0001161697-26-000060:1
1,628 shares@ US$4.2813.9% of flowCommon StockSEC:0001161697-26-000062:1
5,756 shares@ US$4.283.4% of flowCommon StockSEC:0001161697-26-000058:1
5,064 shares0Common StockSEC:0001161697-26-000062:0
5,404 shares0Common StockSEC:0001161697-26-000060:0
15,968 shares0Common StockSEC:0001161697-26-000058:0
750,000 shares0Common StockSEC:0001161697-26-000041:1
25 of 557 declarations
About KORU Medical Systems, Inc.
KORU Medical Systems, Inc. (ticker: KRMD) is a U.S.-based medical device company listed on the NASDAQ in the United States. For French-speaking investors, it fits the profile of a niche medtech focused on large-volume subcutaneous infusion solutions rather than pharmaceuticals. The company was incorporated in 1980 and is headquartered in Mahwah, New Jersey. Its business model is centered on a specialized segment of healthcare delivery where ease of use, reliability, and patient convenience are key differentiators. ([stockanalysis.com](https://stockanalysis.com/stocks/krmd/company/?utm_source=openai))
KORU Medical develops, manufactures, and commercializes patient-centric infusion systems used to administer therapies subcutaneously, including in the home and in ambulatory care settings. Its flagship platform is the Freedom System, which first received FDA clearance in 1994. The company also highlights FreedomEDGE, a syringe/infusion system designed for subcutaneous administration in home care, infusion centers, and other medical environments. In practical terms, KORU serves therapy areas that require repeated or specialized delivery of treatments, with an emphasis on portability, convenience, and patient experience. ([investors.korumedical.com](https://investors.korumedical.com/news-events/press-releases/detail/192/koru-medical-systems-reports-preliminary-q4-and-full-year-2025-results-achieves-record-revenue-and-full-year-positive-operating-cash-flow?utm_source=openai))
Read moreShow less
From a competitive standpoint, KORU operates in a focused niche where its long-standing technical know-how and installed base matter, but where it remains much smaller than the global medtech giants. Its competitive edge comes from specialization, application expertise, and the ability to partner with pharmaceutical and care-delivery organizations. Recent company communications suggest improving commercial momentum: in 2025, KORU reported revenue growth, improved adjusted operating profitability, and positive operating cash flow for fiscal 2025, while also raising revenue guidance. The company also announced a next-generation subcutaneous immunoglobulin infusion agreement in 2025 and presented clinical data in Europe, indicating both product development and broader geographic outreach. ([investors.korumedical.com](https://investors.korumedical.com/news-events/press-releases/detail/195/koru-medical-systems-announces-20-fourth-quarter-and-full-year-2025-revenue-growth-positive-adjusted-ebitda-and-initiates-full-year-2026-guidance?utm_source=openai))
Geographically, KORU remains primarily U.S.-anchored, but recent filings and disclosures show meaningful international activity and contribution to growth. For investors in France, Belgium, and Switzerland, KRMD should therefore be viewed as a U.S.-listed NASDAQ small-cap healthcare name with exposure to specialty medical devices, home infusion adoption, and the growing use of subcutaneous delivery pathways. The investment case is best understood as a specialized growth story, driven by execution, clinical and commercial partnerships, and expanding use cases rather than broad diversification across healthcare. ([investors.korumedical.com](https://investors.korumedical.com/sec-filings/all-sec-filings/content/0001161697-26-000107/0001161697-26-000107.pdf?utm_source=openai))
